Access Strategy

Commercialising biopharmaceutical products in global markets presents multiple challenges:

Heterogeneous patient populations, treatment practices, and other epidemiological factors
Complex healthcare systems, with intricate market access and funding pathways
Constrained healthcare budgets, with increasing controls over pharmaceutical expenditure
Exacting evidence requirements, with assessment methodologies that vary by market
Variance in affordability and willingness to pay, with exposure to cross-market pricing risks

At Precision AQ, we understand that developing a successful global market access strategy is a complex exercise. We help our clients navigate their way through the complexities of the world’s pharmaceutical markets, developing the supporting evidence and strategies that will underpin the commercial success of their products.

SPECTRUM OF SERVICES

Health Economics and Outcomes Research

HEOR Strategy

We develop and implement HEOR strategies to ensure that the right evidence supporting your healthcare innovation meets the demands of payers, HTA organisations, policymakers, and other healthcare stakeholders.

Evidence Synthesis

We leverage state-of-the-art evidence synthesis techniques—network meta-analyses, population-adjusted indirect comparisons, external controls, validation of surrogate endpoints, and living evidence synthesis—to overcome gaps in the evidence base and to understand the value of your healthcare innovation.

Health Economic Modeling

We develop credible evidence-based health economic models to quantify the value and population health impact of your healthcare innovation: cost-effectiveness and budget impact models to support HTA submissions and payer discussions, generalised cost-effectiveness analyses incorporating novel elements of value, treatment sequence comparisons, and health equity impact evaluations with distributional cost-effectiveness analysis.

Real-World Evidence

We quantify disease burden, treatment patterns, and treatment effects and assess patient, provider, and payer preferences using a wide range of existing RWE data sources and primary data collection.

PRICING & MARKET ACCESS

Payer Landscape Assessment

Prior to any product launch, it is critical to understand the market environment you’re entering. Our market experts apply a structured approach to characterising the payer landscape, including the disease burden and unmet needs, current treatment practices, HTA and pricing information, competitive dynamics, and pipeline activity. We also specialise in stakeholder mapping, access and funding pathways, and analogue analyses.

HTA Planning and Engagement

We have a deep understanding of the evidence requirements and decision-making processes that govern the different health technology assessment (HTA) agencies around the globe. We help our customers in preparing for their HTA submissions—through a mix of early scientific advice, payer advisory boards, analogue analysis, and other forms of research.

Price-Access Optimisation

We provide pricing strategies for our clients across the product life cycle, from early P&MA assessments through to global launch pricing and loss-of-exclusivity planning. We apply rigorous pricing research methodologies, coupled with sophisticated modelling techniques, to inform international price-referencing, launch-sequencing, and cross-indication pricing risks.

Payer Value Communications

We are experts in developing payer value communication materials, including value propositions, objection handlers, FAQs, negotiation guides, and more. We pair our P&MA expertise with our digital and communications capabilities to craft positioning and messaging strategies that really resonate with payers.